Overview

Renal Impairment Study

Status:
Completed

Trial end date:
2010-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to see how quickly AZD3355 is taken up in to the blood and leaves the blood in people with normal kidney function or with different degrees of reduced kidney function.

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca

Treatments:

Lesogaberan